Does Mitotane have a therapeutic effect on cancer embolism?

Mitotane is a type of special drug mainly used to treat adrenocortical tumors (adrenal cancer). Its unique mechanism comes from its selective effect on adrenocortical cells. It can interfere with the synthesis pathway of adrenal hormones and exert an inhibitory effect on abnormal cells. Therefore, it has been included in international treatment guidelines for patients with adrenocortical cancer for a long time. Many patients will be concerned about a more specific question: Does mitotane have a therapeutic effect on "tumor thrombus"? To answer this point, it is necessary to distinguish whether the "shrinking effect of the tumor itself" and the "direct removal of tumor thrombus" belong to the same concept.

Cancer thrombus often refers to a mass formed after tumor cells invade the blood vessel lumen. Its formation involves factors such as the infiltration ability of tumor cells, changes in local tissue structure, and hemodynamic effects. The mechanism of mitotane is essentially to inhibit the growth of tumor tissue by affecting the metabolism and function of adrenocortical cells. It does not physically dissolve cancer thrombi, nor does it clear intravascular tissue by rapidly killing tumor cells, so its ability to directly act on cancer thrombus is limited.

Mitotan can change the growth rate of tumor cells and control the tumor burden in some patients. Logically, this may have an indirect effect on the growth of tumor thrombus. For example, if the primary tumor enters a stable state under mitotane treatment, the progression of the tumor thrombus may slow down, but whether it will shrink significantly or disappear completely depends on the structure of the tumor thrombus itself and the attachment to the blood vessel wall. Cancer thrombus is more like an "established pathological structure" rather than a simple tissue that can be directly removed by drugs. Therefore, when discussing treatment options, most doctors will focus on surgery, radiation, luminal intervention and other measures, and will not regard mitotane as a "cancer thrombus treatment drug."

Reference materials:https://go.drugbank.com/drugs/DB00648